Daniel Von Hoff

Who is Daniel Von Hoff?

Daniel D. Von Hoff, M.D., F.A.C.P. has been a member of Genta's Board since

January 2000. He also serves as Executive Vice President of the

Translational Genomics Research Institute (TGen), Phoenix, Arizona and

Director of TGen's Translational Drug Development Division. Dr. Von

Hoff is also Chief Scientific Officer for U.S. Oncology. From 1985

through 1999, he was a professor at the University of Texas Health

Science Center at San Antonio. In 1999 he became Professor of Medicine,

Pathology and Molecular Biology and Director of the Arizona Cancer

Center, University of Arizona. He recently stepped down from that

position to join TGen to translate new discoveries from the research

bench into the clinic. Dr. Von Hoff has published more than 513 papers,

127 book chapters and more than 854 abstracts. Dr. Von Hoff is the

former President of the American Association for Cancer Research, a

Fellow of the American College of Physicians and a member and past

board member of the American Society of Clinical Oncology. He was a

founder and board member of ILEX™ Oncology, Inc., which was acquired by

Genzyme, Inc., in 2004. Dr. Von Hoff has also served as a consultant to

a number of biopharmaceutical companies engaged in oncology drug

development. He is founder and the Editor Emeritus of Investigational

New Drugs - The Journal of New Anticancer Agents and Editor of

Molecular Cancer Therapeutics. He has played a significant role in the

development of several anticancer agents, e.g., gemcitabine, CPT-11,

docetaxel and many others now used routinely in the practice of

oncology.